Medical Abortion
28
0
1
22
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
10.7%
3 terminated out of 28 trials
88.0%
+1.5% vs benchmark
43%
12 trials in Phase 3/4
14%
3 of 22 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 22 completed trials
Clinical Trials (28)
Effectiveness and Safety of Combination Mifepristone/Misoprostol for Medical Abortion
Requests for Voluntary Termination and Medical Termination of Pregnancy for Maternal, Psychological or Social Reasons At the Women's Center ( La Maison Des Femmes) in Saint-Denis :
Mifepristone and Two Doses of Misoprostol for Abortion at 11&12 Weeks
Methadone and Medication Abortion
Assessment of Pain During an Abortion With Knowledge of the Predictive Factors of Pain.
Midlevel Versus Physician-provided Medical Abortion in the Second Trimester
Cannabinoids for Pain Control During Medical Abortion
Medical Abortion Self-Confirmation (MASC)
Acceptability and Feasibility of Medical Abortion in Singapore
Simplifying First Trimester Medical Abortion Follow-up
Self-Assessment of Medical Abortion Outcome Using Serial Multi-level Pregnancy Tests
Outpatient Medical Abortion With Mifepristone and Misoprostol Through 77 Days of Gestation
Medical Abortion at Gestational Age of 8 to ≤9 Weeks Versus >9 to ≤12 Weeks
Quickstart of Nexplanon® at Medical Abortion
Exploring the Role of At-home Semi-Quantitative Pregnancy Tests for Medical Abortion Follow-up
Simplifying Menstrual Regulation (MR): Post Abortion Care in Pakistan
Effectiveness of Pregnancy Tests as an Assessment Tool to Identify Continuing Pregnancy
Acceptability of an Out-patient Regimen of Medical Abortion With Mifepristone and 800 Mcg Misoprostol Administered at 78-84 Days Gestation
Safety and Efficacy of Medical Abortion Provided by Midlevel Providers or Physicians
Routine Follow-up Versus Self-assessment in Medical Abortion